KRISTA BROWN: Open Payments
NPI 1629435177 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 33 payments from 15 companies in 2025. Trend: 2023 $508 · 2024 $1,392 · 2025 $1,059
Food & beverage: $1,059
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $229 |
| AstraZeneca Pharmaceuticals LP | 5 | $172 |
| GlaxoSmithKline, LLC. | 2 | $144 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Lilly USA, LLC | 6 | $110 |
| Gilead Sciences, Inc. | 2 | $46 |
| PFIZER INC. | 2 | $44 |
| ABBVIE INC. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $25 |
Products named: AREXVY, AMVUTTRA, Wegovy, BREZTRI, Ozempic, MOUNJARO, AIRSUPRA, VYNDAQEL.
Industry payments across MD — which companies pay providers there.
